Issue link: http://www.e-digitaleditions.com/i/880535
Information about outsourcing that may be useful in research and development or manufacturing. Content is provided by companies, with no preference intended. 30 OctOber 2017 Inhalation Special Section outSourcing ServiceS This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No product endorsement or preference is intended. Bringing advanced inhalation therapeutics to market Capsugel, now a Lonza company, has expanded its late-stage inhala- tion capabilities to advance dry powder inhalation (DPI) concepts through late-stage clinical trial and commercial production. Recently, the company installed a new Harro Höfliger Modu-C MS encapsula- tion unit that offers specialized drum-dosing technology for use in DPI development projects utilizing spray-dry processing. The invest- m e n t s t r e n g t h e n s C a p s u g e l ' s full-service inhalation product development capabilities, which include proprietary spray-dry pro- cessing, specialized CMC/analytical services and encapsulation capacity to support development, clinical trial and commercial-scale projects. Capsugel US: +1 888 783-6361 www.capsugel.com Accelerating drug product development Next Breath is a full-service, cGMP-compliant laboratory specializing in the analytical testing of drug delivery systems. Next Breath provides compre- hensive solutions for the product development process, from formulation and CMC support to finished batch release and post-approval stability stud- ies. With each analysis, customers receive detailed reports and one-on-one explanations of results from a team of dedicated scientists. Next Breath US: +1 410 455-5904 www.nextbreath.net MDI and DPI product development Pulmonary drug delivery provides targeted, localized therapy for a broad range of disease areas, including allergic, infectious and pulmonary diseases. It also provides systemic therapeutics for central nervous system (CNS) and metabolic diseases. e team at Recipharm has extensive experience in help- ing clients with inhalation product development for both metered dose inhalers (MDIs) and dry powdered inhalers (DPIs) to help meet regulatory milestones for clinical and commercial development. Recipharm Sweden: +46 8 602 52 00 www.recipharm.com